

The Ginsenoside Metabolite Compound K Inhibits Toll-like Receptor 4-mediated Inflammatory Signals Acting through Glucocorticoid Receptor

Running title: Compound K Regulates TLR4-dependent Signaling

Chul-Su Yang¹, Sung-Ryong Ko³, Byung-Goo Cho³, Hyun-Joo Sohn³, Jae-Ho Do³, Young-Sook Kim³, Shengjin Li², Jin-Man Kim^{2,4}, Chang-Hwa Song¹, and Eun-Kyeong Jo^{1,4*}

Department of Microbiology¹, and Pathology², Research Institute for Medical Sciences⁴, College of Medicine, Chungnam National University, Daejeon 301-747, ³Ginseng Research Group, KT&G Central Research Institute, 302 Shinseong-dong, Yuseong-gu, Daejeon 305-805, S. Korea.

*To whom correspondence should be addressed:

Department of Microbiology, College of Medicine, Chungnam National University, 6 Munhwa-dong, Jungku, Daejeon 301-747, S. Korea.

Phone: 82-42-580-8243. Fax: 82-42-585-3686. E-mail: hayoungi@cnu.ac.kr

Abstract

Compound K (C-K), a protopanaxadiol ginsenoside metabolite, demonstrated immunomodulatory effects in previous studies. Here we describe a novel therapeutic role of CK for the treatment of lethal sepsis through TLR4-associated signaling modulation acting via glucocorticoid receptor (GR) engagement. Of various TLR stimulations, C-K significantly represses TLR4/lipopolysaccharide (LPS)-induced NF-kB and mitogen-activated protein kinase activation, and secretion of proinflammatory cytokines in mononuclear phagocytes. C-K competed for binding of the synthetic glucocorticoid dexamethasone to GR and activated GRE-containing reporter plasmids in a dose-dependent manner. In addition, blockade of GR with the glucocorticoid antagonist RU486 substantially reversed the anti-inflammatory effects of CK. Further, TLR4-dependent repression of inflammatory response genes by C-K was mediated through disrupting p65/interferon regulatory factor (IRF) complexes. Collectively, these results demonstrate that the C-K, as a functional ligand of GR, plays an essential role for controlling the distinct TLR4-mediated inflammatory responses.

Key Words: Compound K, toll-like receptor 4, MAPK, NF-κB